Marko Skelin MPharm PhD

Clinical pharmacy specialist, oncology, pharmacotherapy, T2DM

[Marko Skelin MPharm PhD @MarkoSkelin]

#Polypharmacy, potentially #inappropriate medication and drug-to-drug #interactions effect on overall #survival, time to thrombosis, bleeding and transformation risks in patients with #myeloproliferative neoplasms.
https://t.co/QbbpodetZW

[Clement Haeck PhD, PharmD, MS 🇪🇺🇫🇷 @ClemHaeck]

Congratulations @hung_matthew & everyone behind this @FIP_org guidance on #cancer care!
@ISOPPorg @ESCPNews @MayoCancerCare @NCCN @MarkoSkelin @darconn #TwitteRx #PharmacyHour #NCDs #oncology #pharmacists

[Cristina Ibáñez @cribanec]

Proud of represent @ICO_oncologia @gedefo_sefh @gedefo_sefh in #5ECOP in #Hamburg , taling about #RWD and our experience

With @MarkoSkelin and @RobertTerkola

[Marko Skelin MPharm PhD @MarkoSkelin]

#Ovarian cancer (OC) is the third most common #gynecologic #cancer.
We have evaluated the effect of #PARP inhibitors
in this particular #HRD-#BRCA- of #OC where the effect of PARP inhibitors was not clear until now.

https://t.co/4adt8Mmeux

[Marko Skelin MPharm PhD @MarkoSkelin]

#Ovarian cancer (OC) is the third most common #gynecologic #cancer.
We have evaluated the effect of #PARP inhibitors
in this particular #HRD-#BRCA- of #OC where the effect of was not clear until know.
https://t.co/4adt8Mmeux

[Marko Skelin MPharm PhD @MarkoSkelin]

Is it possible that patient with concomitant #polycythemia vera and multiple sclerosis can be successfully treated for both diseases with #glatiramer acetate? Our case report just out of the press from @SpringerNature #Annals of #Hematology.

[Marko Skelin MPharm PhD @MarkoSkelin]

Can therapeutic drug monitoring be used as a great tool for clinicians to tailor infliximab therapy in patients with inflammatory bowel disease ?
Our comment just published in @JAMA_current.
#JAMA #IBD #Infliximab #TDM

https://t.co/2VLz9Qrse2

[Reviews in Cardiovascular Medicine @RCMjournal]

#RCM - Vol. 23 No. 1
🩺Original Research
Comparison of media and academic attention of recently published positive and neutral or negative randomized cardiovascular clinical trials

#Altmetric #Cardiovascular #RCTID
@MarkoSkelin

Fulltext:
https://t.co/PzfyTz155G

[Pep Guiu @pepguiu]

A great roundtable today about “Innovation in cancer prevention, screening and management in community and hospital pharmacy”
#WorldCancerDay #CloseTheCareGap
@FIP_org @FIP_HPS @FIP_CPS @gspinto_fip @DuncombeRob @MarkoSkelin @PGEU @CSC_Consorci

[Marko Skelin MPharm PhD @MarkoSkelin]

Just published paper on reactive #thrombocytosis in #COVID-19 patients shows that higher #platelets bear more favorable prognosis but higher incidence of venous thrombosis, providing a potential mechanism behind observations reported in #MPN patients
https://t.co/QS0vd6vjIZ

[Marko Skelin MPharm PhD @MarkoSkelin]

Looking forward to a discussion regarding cancer #treatment #challenges with colleagues from the #Children’s #Cancer #Hospital Egypt 57357 (CCHE).
https://t.co/zcyNO8o8i4

[Marko Skelin MPharm PhD @MarkoSkelin]

Are we leveraging aspirin maximum potential? The difference in @BMI may affect @aspirin metabolism and efficacy. More on this topic in our latest letter to the editor in @NEJM.

https://t.co/fCrYIJ2qh5

[Marko Skelin MPharm PhD @MarkoSkelin]

#HPV+oropharyngeal cancer is associated with improved survival and reduced recurrence rates. These outcomes have led in consideration of de-escalation treatment options in order to spare patients from unnecessary toxicity.
#oropharyngealcancer #trialdesign
https://t.co/4XWdDriPzT

[Marko Skelin MPharm PhD @MarkoSkelin]

We are proud to join discussion on the role of #colchicine in treatment of chronic #coronaryheartdisease. Colhicin emerges as a new therapy in patients with #MI and #CAD. However, its real benefit might be reserved for just a subgroup of patients. @NEJM
https://t.co/YyP8h921le

[Tit Albreht @TitAlbreht]

Final conference of WP5 of @iPAAC_project on cancer prevention with interactive group work planned for this afternoon @CancerLeagues @NIJZ_pr @CancerFinland @IARC_DIR @IARCWHO @EU_Health @cancercode

[Marko Skelin MPharm PhD @MarkoSkelin]

#TELESTO trial aimed to prove efficacy and safety of #deferasirox in patients with lower risk #myelodysplastic syndromes. However, conclusions do not bear strength of phase III evidence due to selection bias associated with high droput rates and patient crossover. @AnnalsofIM

[Marko Skelin MPharm PhD @MarkoSkelin]

#ARISTOPHANES study showed increased risk of ischemic #stroke in #obese #AFib #dabigatran patients and higher risk of GI #bleeding in obese #rivaroxaban patients.
These exciting findings had independently validated our already published pioneer results. https://t.co/vDfieWPfLU

[Marko Skelin MPharm PhD @MarkoSkelin]

Clear understanding of the nature and interpretation of #COVID19 test is extremely important!
Useful timeline of diagnostic markers for #COVID19 detection is nicely presented in recent paper by Seturaman published in @JAMA_current.
#diagnostics #testing
https://t.co/6SvcyY8p41

[Marko Skelin MPharm PhD @MarkoSkelin]

Currently there are 182 #randomized #Phase 3 #trials investigating various interventions against #COVID19. If all those interventions are inactive, will still get at least 5 falsely positive trials to look forward?
https://t.co/dkxe9gfsOT

[Marko Skelin MPharm PhD @MarkoSkelin]

Study just published in @NEJM rejects association between #ACE inhibitors and #ARB use and an increased likelihood of a positive test for #COVIDー19.

https://t.co/HBUjschi4N